Quality of Life Issues of Patients with Multiple Myeloma

Gadó, Klára; Domján, Gyula

doi:10.5772/55625

Cited by 7 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the goal of new therapies and combinations of therapies is primarily to extend overall survival and PFS, HR-QoL is also of key importance. 2,30,31 With longer survival times, patients live longer with what remains an incurable disease. The ASPIRE trial had HR-QoL as a prespecified secondary end point measured by the GHS/QoL subscale, which provides a measure of the overall impact of MM and its treatment from the patient's perspective.…”

Section: Discussionmentioning

confidence: 99%

Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma

Stewart

Dimopoulos

Masszi

et al. 2016

JCO

View full text Add to dashboard Cite

Purpose To determine the effects of carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) on health-related quality of life (HR-QoL) in the Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone for the Treatment of Patients With Relapsed Multiple Myeloma (ASPIRE) trial. Methods Patients with relapsed multiple myeloma were randomly assigned to receive KRd or Rd. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 and myeloma-specific module were administered at baseline; day 1 of cycles 3, 6, 12, and 18; and after treatment. The Global Health Status/Quality of Life (GHS/QoL) scale and seven subscales (fatigue, nausea and vomiting, pain, physical functioning, role functioning, disease symptoms, and adverse effects of treatment) were compared between groups using a mixed model for repeated measures. The percentages of responders with ≥ 5- or 15-point GHS/QoL improvement at each cycle were compared between groups. Results Baseline questionnaire compliance was excellent (94.1% of randomly assigned patients). KRd patients had higher GHS/QoL scores versus Rd patients over 18 treatment cycles (two-sided P < .001). The minimal important difference was met at cycle 12 (5.6 points) and approached at cycle 18 (4.8 points). There was no difference between groups for the other prespecified subscales from ASPIRE. A higher proportion of KRd patients met the GHS/QoL responder definition (≥ 5-point improvement) with statistical differences at cycle 12 (KRd v Rd patients, 25.5% v 17.4%, respectively) and 18 (KRd v Rd patients, 24.2% v 12.9%, respectively). Conclusion KRd improves GHS/QoL without negatively affecting patient-reported symptoms when compared with Rd. These data further support the benefit of KRd in patients with relapsed multiple myeloma.

show abstract

Section: Discussionmentioning

confidence: 99%

Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma

Stewart

Dimopoulos

Masszi

et al. 2016

JCO

View full text Add to dashboard Cite

show abstract

“… Gadó & Domján (2013) describe MM as a chronic, incurable disease that may be associated with a reduction in QOL. Pathologic bone fracture, bone pain, fatigue due to anemia and malignant disease itself, and neurologic symptoms that may be associated with hypercalcemia may impact the HRQoL of patients with MM.…”

Section: Disease-specific Side Effectsmentioning

confidence: 99%

“…Many of the therapies for MM are administered via IV injections or infusions and are given frequently, even weekly. Routine laboratory check-ups, repeated blood sample collections that may require painful needlesticks, and bone marrow aspiration and biopsy are frequently required for diagnosis and monitoring of the disease response and recurrence ( Gadó & Domján, 2013 ). All of these procedures have an impact on a patient’s HRQoL.…”

Section: Disease-specific Side Effectsmentioning

confidence: 99%

“…Potential treatment with stem cell transplantation poses considerable effects as well, as does high-dose chemotherapy. In addition, infection, mucositis, increased use of blood products, and extended or recurrent hospital admissions affect HRQoL ( Gadó & Domján, 2013 ).…”

Section: Disease-specific Side Effectsmentioning

confidence: 99%

“…Quality of life has become an important endpoint in recent, randomized clinical trials ( Roussel et al, 2020 ; Schjesvold et al, 2020 ). Gadó & Domján (2013) state that studies that have demonstrated a reduction in HRQoL in patients with MM have determined that HRQoL assessment should become part of routine clinical care. Clinical trials should include HRQoL as a study endpoint as well be considered as a potential primary endpoint for future studies.…”

Section: Evidence For Using Qol Tools In Clinical Practicementioning

confidence: 99%

See 2 more Smart Citations

Patient-Reported Outcomes and Assessment of Quality of Life: A Focus on Multiple Myeloma

Fragola¹

2020

JADPRO

View full text Add to dashboard Cite

Patients with multiple myeloma are living longer, yet the chronicity of newer treatment modalities has led to increased symptom burden and a notable effect on quality of life (QOL). The assessment of QOL and evaluation of patient-reported outcomes is an essential element to the care of this population. Patients with MM may experience unwanted side effects or disease-related symptoms that create a burden in everyday living. Subjective patient-reported information has become an important dimension to the overall care and treatment of these patients. Symptoms that negatively affect health-related quality of life (HRQoL) and their impact on future treatments should be assessed using patient-reported tools. Many patients’ treatment decisions are guided by their perception of their HRQoL. It is important for advanced practitioners to explore which factors are most impactful to the patient. Improved understanding of this can further enhance the management of symptoms and adjustments in treatment to avoid further reduction in HRQoL.

show abstract

Treatment-related symptom management in patients with multiple myeloma: a review

Colson

2015

Support Care Cancer

View full text Add to dashboard Cite

show abstract

Quality of Life Issues of Patients with Multiple Myeloma

Cited by 7 publications

References 31 publications

Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma

Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma

Patient-Reported Outcomes and Assessment of Quality of Life: A Focus on Multiple Myeloma

Treatment-related symptom management in patients with multiple myeloma: a review

Contact Info

Product

Resources

About